Adrenal cortex: Edited by Ellen W. SeelyCongenital adrenal hyperplasia in adultsAuchus, Richard JAuthor Information Division of Endocrinology and Metabolism, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA Correspondence to Richard J. Auchus, Division of Endocrinology and Metabolism, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8857, USA Tel: +1 214 648 6751; fax: +1 214 648 8917; e-mail: Richard.Auchus@UTSouthwestern.edu Current Opinion in Endocrinology, Diabetes and Obesity: June 2010 - Volume 17 - Issue 3 - p 210-216 doi: 10.1097/MED.0b013e32833961d7 Buy Metrics Abstract Purpose of review Patients born with congenital adrenal hyperplasia (CAH), the majority of which is 21-hydroxylase deficiency (21OHD), have been studied by pediatric endocrinologists for decades and treated successfully since the pioneering work of Lawson Wilkins. As is the case for other previously fatal diseases of childhood, such as type 1 diabetes mellitus and cystic fibrosis, these children are now surviving into adulthood. This success has created a new clinical entity, for which the natural history and optimal management strategies are not known. Recent findings Longitudinal and cross-sectional studies of adults with CAH have begun to emerge from a few centers. The major challenges faced by these patients include infertility, neoplasia, and consequences of chronic glucocorticoid therapy. Summary The treatment goals of the adult with CAH differ from those for children, and data from specialized centers have identified some of the major issues guiding management. More data and better therapies for these patients are sorely needed. © 2010 Lippincott Williams & Wilkins, Inc.